1. Home
  2. KALV vs FFIC Comparison

KALV vs FFIC Comparison

Compare KALV & FFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$15.48

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Logo Flushing Financial Corporation

FFIC

Flushing Financial Corporation

HOLD

Current Price

$14.66

Market Cap

536.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
FFIC
Founded
N/A
1929
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
536.1M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
KALV
FFIC
Price
$15.48
$14.66
Analyst Decision
Strong Buy
Hold
Analyst Count
5
1
Target Price
$30.00
$16.80
AVG Volume (30 Days)
721.4K
178.5K
Earning Date
03-25-2026
04-28-2026
Dividend Yield
N/A
6.00%
EPS Growth
N/A
151.43
EPS
N/A
0.54
Revenue
$50,000,000.00
$7,455,000.00
Revenue This Year
N/A
$14.57
Revenue Next Year
N/A
$6.64
P/E Ratio
N/A
$27.15
Revenue Growth
495.66
7.31
52 Week Low
$9.83
$10.65
52 Week High
$19.00
$17.79

Technical Indicators

Market Signals
Indicator
KALV
FFIC
Relative Strength Index (RSI) 45.58 31.68
Support Level $14.59 $14.44
Resistance Level $16.49 $16.99
Average True Range (ATR) 0.98 0.38
MACD -0.06 -0.10
Stochastic Oscillator 13.35 1.43

Price Performance

Historical Comparison
KALV
FFIC

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About FFIC Flushing Financial Corporation

Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.

Share on Social Networks: